- Report
- October 2025
- 194 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 195 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 190 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 191 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 188 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 180 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 187 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 192 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 188 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 199 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 193 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 193 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 198 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 194 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 185 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 180 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 196 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 198 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 185 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 195 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more